
Khyati Girdhar, PhD
Assistant Professor, Pediatrics (Endocrinology)
Locations
- TBRC/CRI
- 2nd Floor, C2570
8701 Watertown Plank Rd,
Milwaukee, WI 53226
Contact Information
Honors and Awards
2022, D-challenge Award
Research Interests
My lab research focused on understanding the environmental factors which play a fundamental role in shaping immune responses and influencing Type 1 Diabetes (T1D) progression. Our research program is dedicated to understanding how the gut microbiome interacts with the immune system, identifying key microbial players that either protect against or promote autoimmunity.
In my lab, we determine:
- Why and which microbes are specifically interacting with the immune system by utilizing new sequencing techniques?
- How do these gut microbes and immune interactions evolve as disease progresses to help us identify new Biomarkers?
- How the functional molecules e.g. proteins, metabolites, and exosomes secreted by microbiota influence immune cell behavior during T1D development
Beyond identifying microbial triggers, our research work also focuses on translating these findings into therapeutic strategies. One of our primary research areas is the development of new probiotics and also engineering probiotic therapies to induce immune tolerance or reduce inflammation, slow disease progression, and reduce complications in T1D patients.
We believe our research will help in predicting, preventing, and managing T1D: 1) By identifying Early Detection & Biomarkers. 2) by utilizing microbial-based therapies to restore immune balance and 3) by determining individual variations in microbiome-immune interactions to develop personalized treatment strategies.
Get Involved
For Researchers & Clinicians: Collaborate with us to advance microbiome-based immunotherapies.
For Students & Trainees: Explore research opportunities and contribute to T1D Research.
For Patients & Public: Stay informed – Follow us on Social Media (LinkedIn | X: @GirdharKhyati) for updates
Publications
-
Sex-specific cytokine, chemokine, and growth factor signatures in T1D patients and progressors.
(Girdhar K, Mine K, DaCosta JM, Atkinson MA, Ludvigsson J, Altindis E.) FASEB J. 2024 Dec 13;38(24):e70270 PMID: 39704278 PMCID: PMC11660211 12/20/2024
-
Sex-Specific Cytokine, Chemokine, and Growth Factor Signatures in T1D Patients and Progressors.
(Girdhar K, Mine K, DaCosta JM, Atkinson MA, Ludvigsson J, Altindis E.) bioRxiv. 2024 Sep 07 PMID: 39282401 PMCID: PMC11398455 09/17/2024
-
(Girdhar K, Dogru YD, Huang Q, Yang Y, Tolstikov V, Raisingani A, Chrudinova M, Oh J, Kelley K, Ludvigsson JF, Kiebish MA, Palm NW, Ludvigsson J, Altindis E.) Microbiome. 2023 Jan 13;11(1):9 PMID: 36639805 PMCID: PMC9840338 01/14/2023
-
A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes.
(Girdhar K, Huang Q, Chow IT, Vatanen T, Brady C, Raisingani A, Autissier P, Atkinson MA, Kwok WW, Kahn CR, Altindis E.) Proc Natl Acad Sci U S A. 2022 Aug 02;119(31):e2120028119 PMID: 35878027 PMCID: PMC9351354 07/26/2022
-
(Girdhar K, Thakur S, Gaur P, Choubey A, Dogra S, Dehury B, Kumar S, Biswas B, Dwivedi DK, Ghosh S, Mondal P.) J Biol Chem. 2022 May;298(5):101889 PMID: 35378127 PMCID: PMC9095748 04/05/2022
-
Gut Microbiota Regulate Pancreatic Growth, Exocrine Function, and Gut Hormones.
(Girdhar K, Soto M, Huang Q, Orliaguet L, Cederquist C, Sundaresh B, Hu J, Figura M, Raisingani A, Canfora EE, Dirice E, Fujisaka S, Goossens GH, Blaak EE, Kulkarni RN, Kahn CR, Altindis E.) Diabetes. 2022 May 01;71(5):945-960 PMID: 35212729 PMCID: PMC9044125 02/26/2022
-
Organosulfur/Selenium-Based Highly Fluorogenic Molecular Probes for Live-Cell Nucleolus Imaging.
(Mondal IC, Galkin M, Sharma S, Murugan NA, Yushchenko DA, Girdhar K, Karmakar A, Mondal P, Gaur P, Ghosh S.) Chem Asian J. 2022 Apr 01;17(7):e202101281 PMID: 35129298 02/08/2022
-
Viruses and Metabolism: The Effects of Viral Infections and Viral Insulins on Host Metabolism.
(Girdhar K, Powis A, Raisingani A, Chrudinová M, Huang R, Tran T, Sevgi K, Dogus Dogru Y, Altindis E.) Annu Rev Virol. 2021 Sep 29;8(1):373-391 PMID: 34586876 PMCID: PMC9175272 09/30/2021
-
Low-dose naltrexone rescues inflammation and insulin resistance associated with hyperinsulinemia.
(Choubey A, Girdhar K, Kar AK, Kushwaha S, Yadav MK, Ghosh D, Mondal P.) J Biol Chem. 2020 Nov 27;295(48):16359-16369 PMID: 32943552 PMCID: PMC7705311 09/19/2020
-
(Biswas B, Venkateswarulu M, Sinha S, Girdhar K, Ghosh S, Chatterjee S, Mondal P, Ghosh S.) ACS Appl Bio Mater. 2019 Dec 16;2(12):5427-5433 PMID: 35021541 12/16/2019
-
(Girdhar K, Dehury B, Kumar Singh M, Daniel VP, Choubey A, Dogra S, Kumar S, Mondal P.) J Biomol Struct Dyn. 2019 Sep;37(15):3976-3986 PMID: 30296922 10/10/2018
-
(Dogra S, Kar AK, Girdhar K, Daniel PV, Chatterjee S, Choubey A, Ghosh S, Patnaik S, Ghosh D, Mondal P.) Nanomedicine. 2019 Apr;17:210-222 PMID: 30708053 02/02/2019